

# Global action plan

to control the spread and impact of  
antimicrobial resistance in *Neisseria gonorrhoeae*



World Health  
Organization



Global action plan to control the  
spread and impact of antimicrobial  
resistance in *Neisseria gonorrhoeae*



World Health  
Organization

WHO Library Cataloguing-in-Publication Data

Global action plan to control the spread and impact of antimicrobial resistance in *Neisseria gonorrhoeae*.

1. Drug resistance, microbial. 2. *Neisseria gonorrhoeae* - drug therapy. 3. Gonorrhea - drug therapy. 4. Gonorrhea – prevention and control. 5. Gonorrhea – diagnosis. I. World Health Organization.

ISBN 978 92 4 150350 1

(NLM classification: QW 131)

© **World Health Organization 2012**

All rights reserved. Publications of the World Health Organization are available on the WHO web site ([www.who.int](http://www.who.int)) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site ([http://www.who.int/about/licensing/copyright\\_form/en/index.html](http://www.who.int/about/licensing/copyright_form/en/index.html)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed by the WHO Document Production Services

# Table of contents

Acknowledgements .....	1
Abbreviations .....	3
1. Introduction.....	4
1.1 Vision .....	4
1.2 Objective .....	4
1.3 Summary of strategies .....	5
1.4 Role of stakeholders.....	5
1.5 Key populations.....	7
1.6 Advocacy and resource mobilization .....	7
1.7 Guiding principles in the implementation of the global action plan .....	8
2. Background to a global crisis .....	9
3. Strategies for containing antimicrobial resistance .....	12
3.1 Improving early detection of infection .....	12
3.2 Appropriate and effective treatments for patients and their sexual partners.....	13
3.3 Good compliance.....	13
3.4 Educating the client .....	13
3.5 Strengthening surveillance .....	14
3.6 Laboratory capacity strengthening.....	14
3.7 Regulatory mechanisms .....	15
3.8 Advocacy and communication .....	15
4. Specific responses to cephalosporin-resistant <i>N. gonorrhoeae</i> .....	16
4.1 Early detection of cephalosporin-resistant <i>N. gonorrhoeae</i> by clinicians and laboratory technicians .....	16
4.2 Action for programme managers and STI surveillance staff .....	21
4.3 Research gaps and needs.....	23
Operational research .....	23
Laboratory research.....	24
Applied or field research .....	24
Research and development.....	24
Mathematical modelling.....	24
5. Advocacy and action by the World Health Organization, international partners and national stakeholders .....	25
5.1 The World Health Organization.....	25
5.2 National-level policy-makers .....	26
5.3 International-level partners and donors.....	28
5.4 Communications strategy.....	29
References.....	32



## Acknowledgements

This document was coordinated in the WHO Department of Reproductive Health and Research (RHR) by Francis Ndowa and Manjula Lusti-Narasimhan based on the extensive work carried out by (late) John Tapsall (Sydney, Australia) and Magnus Unemo (Orebro, Sweden) and in collaboration with the other members of the Gonococcal Antimicrobial Surveillance Programme (GASP). We thank Dr Ye Tun (CDC-USA) for drafting the outline of the document following recommendations from the meeting of experts held in Manila, the Philippines, in 2010. The document was revised and updated after an international consultation on the *Global implementation of GASP* held in Geneva from 8 to 10 June 2011. The revised document was further reviewed by, and technical input was received from, Manju Bala, Gail Bolan, Kevin Fenton, Cathy Ison and Magnus Unemo.

We thank the following WHO colleagues for their contributions: Iyanthi Abeyewickreme, Saliya Karymbaeva, Lali Khotenashvili, Lori Newman, Pilar Ramon-Pardo, Igor Toskin and Teodora Elvira Wi.

We would also like to thank the following partners for their valuable participation in the meeting held in Geneva in June 2011, and for their information, data and advice that enabled the development of this action plan:

**Christine Awuor**, National AIDS and STI Control Programme, Nairobi, Kenya

**Manju Bala**, WHO GASP SEAR Regional Reference Laboratory, VMMC and Safdarjang Hospital, New Delhi, India

**Gail Bolan**, Sexually Transmitted Disease Prevention Program (DSTDP), National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention (CDC), Atlanta, United States of America

**John Changalucha**, National Institute for Medical Research, Mwanza Medical Research Centre, Mwanza, United Republic of Tanzania

**Michelle Cole**, Sexually Transmitted Bacteria Reference Laboratory, Health Protection Agency, London, United Kingdom of Great Britain and Northern Ireland

**Carolyn Deal**, National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, United States of America

**Jo-Anne Dillon**, University of Saskatchewan, Saskatoon, Canada

**Kevin Fenton**, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention (CDC), Atlanta, United States of America

**Patricia Galarza**, Sexually Transmitted Infections Reference Centre, National Institute of Infectious Diseases, Buenos Aires, Argentina

**Amina Hançali**, STD Laboratory, Bacterial Department, National Institute of Hygiene, Rabat, Morocco

**Catherine Ison**, Sexually Transmitted Bacteria Reference Laboratory, Health Protection Agency Centre, Colindale, London, United Kingdom of Great Britain and Northern Ireland

**Lilani Indrika Karunanayake**, Medical Research Institute, Colombo, Sri Lanka

**Monica M Lahra**, WHO Collaborating Centre for STD, South Eastern Area Laboratory Services (SEALS), Sydney, Australia

**David Lewis**, Sexually Transmitted Infections Reference Centre, National Institute of Communicable Diseases, Johannesburg, South Africa

**Athena Limnios**, WHO Collaborating Centre for STD Microbiology Department, South Eastern Area Laboratory Services (SEALS), The Prince of Wales Hospital, Sydney, Australia

**Anna Machiha**, STI HIV/AIDS and TB Programmes, Ministry of Health and Child Welfare, Harare, Zimbabwe

**Farinaz Rashed Marandi**, Department of Bacteriology, Research Center of Reference Laboratory of Iran, Tehran, Islamic Republic of Iran

**Margaret Mbuchi**, Centre for Clinical Research, Kenya Medical Research Institute (KEMRI), Nairobi, Kenya

**Florence Mueni Mutua**, University of Nairobi, Nairobi, Kenya

**Magnus Unemo**, WHO Collaborating Centre for Gonorrhoea and other STIs, Department of Laboratory Medicine, Microbiology, Orebro University Hospital, Orebro, Sweden

**Hariadi Wisnu Wardana**, STI Prevention and Control, The Ministry of Health of the Republic of Indonesia, Ministry of Health, Jakarta, Indonesia

**Hillard Weinstock**, Epidemiology and Surveillance Branch Division of STD Prevention, Centers for Disease Control and Prevention (CDC), Atlanta, United States of America

**Andi Yasmon**, Microbiologist, Department of Microbiology, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia

**Yin Yue-Ping**, National Reference Laboratory for STD, National Center for STD Control, Chinese Academy of Medical Sciences, Peking Union Medical College Institute of Dermatology, Nanjing, China.

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_28505](https://www.yunbaogao.cn/report/index/report?reportId=5_28505)

